Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.05, compared with -$0.03 a year earlier. Trailing-twelve-month EPS (Diluted) was -$0.1.
Context
- EPS (Diluted) grew in size in 2 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 1 analysts of -$0.12 (+36.8%) for the fiscal year ending Dec 2026, a step up from the -18.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.05-70.6% QoQ
- Last fiscal yearDec 2025
- -$0.19-18.8% YoY
- LTMMar 2026
- -$0.1— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -101.9% | -466.0% | -364.2 pp |
| 1 year | -18.8% | +36.8% | +55.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (0.19) USD
- Year-over-year change
- -18.8%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.19) | -18.8% |
| FY2024 | 2024-12-31 | (0.16) | -700.0% |
| FY2023 | 2023-12-31 | (0.02) | — |
EPS (Diluted) vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's LTM Mar 2026 EPS (Diluted) of -$0.1 is the highest of the 8 companies compared; the peer median is -$3.12.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
PLYXPolaryx Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$0.1 | — | — |
| LTM Mar 2026 | -$1.1 | +27.2% | — | |
| LTM Mar 2026 | -$1.17 | +14.6% | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$2.15 | +85.6% | — |
| LTM Mar 2026 | -$3.12 | +93.1% | — | |
| LTM Mar 2026 | -$10.91 | -442.8% | — | |
| LTM Mar 2026 | -$12.74 | -919.7% | — | |
| LTM Mar 2026 | -$40.69 | -228.1% | — | |
| Peer median (excluding PLYX) | -$3.12 | +14.6% | — | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 2.77M | 2.81M | 6.27M |
| Selling, General & Admin | 1.01M | 1.54M | 1.56M |
| Operating Expenses | 3.78M | 4.35M | 7.82M |
| Depreciation & Amortization | 0 | 0 | 0 |
| EBITDA | (3.78M) | (30.36M) | (8.99M) |
| EBITDA Margin | — | — | — |
| Operating Income | (3.78M) | (4.35M) | (7.82M) |
| Operating Margin | — | — | — |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 2K | (26M) | (1.16M) |
| Income Before Tax | (3.78M) | (30.36M) | (8.99M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.02) | (0.16) | (0.19) |
| EPS (Diluted) | (0.02) | (0.16) | (0.19) |
| Weighted Avg Shares | 189.37M | 189.37M | 47.34M |
| Weighted Avg Shares (Diluted) | 189.37M | 189.37M | 47.34M |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.